Form 8-K AMGEN INC For: Jul 29

Go back to Form 8-K AMGEN INC For: Jul 29

Amgen, Inc. (AMGN) Tops Q2 EPS by 30c

July 29, 2014 4:16 PM EDT

Amgen, Inc. (NASDAQ: AMGN) reported Q2 EPS of $2.37, $0.30 better than the analyst estimate of $2.07. Revenue for the quarter came in at $5.18 billion versus the consensus estimate of $4.9 billion.

Highlights:

Total revenues increased 11 percent to $5,180 million, with 8 percent product sales growth driven by strong performance across the portfolio, particularly Enbrel® (etanercept), Kyprolis® (carfilzomib), Prolia®... More